natgillin/translations-raw huggingface dataset:
In vitro-studier har vist, at ceftarolin er baktericidt og i stand til at hæmme den bakterielle cellevægssyntese i methicillin-resistente Staphylococcus. aureus (MRSA) og ikke-penicillin-følsomme Streptococcus pneumoniae (PNSP), da det bindes til de ændrede penicillin-bindende proteiner (PBP'er), der findes i disse mikroorganismer.
In vitro studies have shown that ceftaroline is bactericidal and able to inhibit bacterial cell wall synthesis in methicillin-resistant Staphylococcus aureus (MRSA) and penicillin non-susceptible Streptococcus pneumoniae (PNSP) due to its affinity for the altered penicillin-binding proteins (PBPs) found in these organisms.
In vitro-studier har vist, at dasabuvir ikke hæmmer den organiske kationtransporter (OCT2), den organiske aniontransporter (OAT3) eller multilægemiddel- og toksinekstrusionsproteinerne (MATE1 og MATE2K) ved klinisk relevante koncentrationer.
In vitro studies show that dasabuvir is not an inhibitor of organic cation transporters (OCT2), organic anion transporters (OAT3), or multidrug and toxin extrusion proteins (MATE1 and MATE2K) at clinically relevant concentrations.
In vitro-studier har vist, at degarelix ikke er et substrat for det humane CYP450- system.
In vitro studies have shown that degarelix is not a substrate for the human CYP450 system.
In vitro-studier har vist, at docetaxels metabolisme kan ændres ved samtidig medicinering med stoffer, som inducerer, hæmmer eller metaboliseres (og således hæmmer enzymet kompetitivt) af CYP3A, f.eks. ciclosporin, ketokonazol og erythromycin .
In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds which induce, inhibit or are metabolised by (and thus may inhibit the enzyme competitively) cytochrome P450-3A such as cyclosporine, ketoconazole and erythromycin.
In vitro-studier har vist, at docetaxels metabolisme kan ændres ved samtidig medicinering med stoffer, som inducerer, hæmmer eller metaboliseres (og således hæmmer enzymet kompetitivt) af cytochrom P450 3A, f.eks ciclosporin, ketoconazol og erythromycin.
In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds which induce, inhibit or are metabolised by (and thus may inhibit the enzyme competitively) cytochrome P450-3A such as ciclosporine, ketoconazole and erythromycin .
In vitro-studier har vist, at docetaxels metabolisme kan ændres ved samtidig medicinering med stoffer, som inducerer, hæmmer eller metaboliseres (og således hæmmer enzymet kompetitivt) af cytochrom P450 3A, f.eks. ciclosporin, ketokonazol og erythromycin.
In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds which induce, inhibit or are metabolised by (and thus may inhibit the enzyme competitively) cytochrome P450-3A such as cyclosporine, ketoconazole and erythromycin.
In vitro-studier har vist, at eltrombopag ikke er et substrat for polypeptidet OATP1B1, der er en organisk anion-transporter, men derimod en hæmmer af denne transporter.
In vitro studies demonstrated that eltrombopag is not a substrate for the organic anion transporter polypeptide, OATP1B1, but is an inhibitor of this transporter.
In vitro-studier har vist, at fase I-metaboliseringen af osimertinib hovedsageligt sker via CYP3A4 og CYP3A5.
In vitro studies have demonstrated that the Phase I metabolism of osimertinib is predominantly via CYP3A4 and CYP3A5.
In vitro-studier har vist, at gefitinib er et substrat for p-glycoprotein (Pgp).
In vitro studies have shown that gefitinib is a substrate of p-glycoprotein (Pgp).
In vitro-studier har vist, at gefitinib potentielt hæmmer CYP2D6 i et begrænset omfang.
In vitro studies have shown that gefitinib has limited potential to inhibit CYP2D6.
In vitro-studier har vist, at ketoconazol kan hæmme granisetrons metabolisme via cytokrom P450 3A- isoenzymfamilien.
In vitro studies have shown that ketoconazole may inhibit the metabolism of granisetron via the cytochrome P450 3A isoenzyme family.
In vitro-studier har vist, at kortikotrope tumorceller fra patienter med Cushings sygdom har et højt hsst5-ekspressionsniveau, mens de andre receptorundertyper enten ikke eksprimeres eller eksprimeres i mindre omfang.
In vitro studies have shown that corticotroph tumour cells from Cushing’s disease patients display a high expression of hsst5, whereas the other receptor subtypes either are not expressed or are expressed at lower levels.
In vitro-studier har vist, at paliperidon er substrat for P-glykoprotein (P- gp).
In vitro studies have shown that paliperidone is a P-glycoprotein (P-gp) substrate.
In vitro-studier har vist, at rosiglitazon primært metaboliseres af CYP2C8 og af CYP2C9 i mindre omfang.
In vitro studies demonstrate that rosiglitazone is predominantly metabolised by CYP2C8, with a minor contribution by CYP2C9.
In vitro-studier har vist, at telaprevir hæmmer OATP1B1 og OATP2B1.
In vitro studies demonstrated that telaprevir is an inhibitor of OATP1B1 and OATP2B1.
In vitro-studier har vist, at tenofoviralafenamid metaboliseres til tenofovir (primær metabolit) af cathepsin A i PBMC’er (herunder lymfocytter og andre hiv-målceller) og makrofager og af carboxylesterase-1 i hepatocytter.
In vitro studies have shown that tenofovir alafenamide is metabolised to tenofovir (major metabolite) by cathepsin A in PBMCs (including lymphocytes and other HIV target cells) and macrophages; and by carboxylesterase-1 in hepatocytes.
In vitro-studier har vist, at vemurafenibhæmmer efflux-transportørerne P-glykoprotein (P-gp) og brystkræft resistent protein (BCRP).
In vitro studies have demonstrated that vemurafenib is an inhibitor of the efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).
In vitro-studier i opicapon-koncentrationsintervallet 0,3 til 30 mikrog/ml viste, at bindingen af
In vitro studies over the opicapone concentration range 0.3 to 30 mcg/mL showed that binding of
In vitro-studier i rotte-hepatocytter har desuden vist, at ambrisentan ikke inducerede ekspression af P- gp, BSEP eller MRP2.
In vitro studies in rat hepatocytes also showed that ambrisentan did not induce Pgp, BSEP or MRP2 protein expression.
In vitro-studier indikerede, at ivacaftor har potentialet til at hæmme CYP2C9.
In vitro studies indicated that ivacaftor has the potential to inhibit CYP2C9.
In vitro-studier indikerer, at boceprevir primært gennemgår metabolisme gennem den aldo-keto- reduktase (AKR)-medierede vej til keton-reducerede metabolitter, der er inaktive over for hcv.
Studies in vitro indicate that boceprevir primarily undergoes metabolism through the aldo- ketoreductase (AKR)-mediated pathway to ketone-reduced metabolites that are inactive against HCV.
In vitro-studier indikerer, at CYP2D6 og CYP3A4 muligvis er minimalt involveret i metaboliseringen af paliperidon, men der er ingen indikationer, hverken in vitro eller in vivo, på, at disse isozymer spiller en signifikant rolle i metaboliseringen af paliperidon.
In vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, but there are no indications in vitro nor in vivo that these isozymes play a significant role in the metabolism of paliperidone.
In vitro-studier indikerer, at CYP3A4-metabolisering og glukuronidering er ansvarlige for metabolisering af vemurafenib.
In vitro studies suggest that CYP3A4 metabolism and glucuronidation are responsible for the metabolism of vemurafenib.
In vitro-studier indikerer, at de aktive metabolitter M-2 og M-5 er substrater for P-glykoprotein og BCRP.
In vitro studies indicate that the active metabolites M-2 and M-5 are substrates for P-glycoprotein and BCRP.
In vitro-studier indikerer, at lenalidomid ikke er et substrat for humant brystcancer-resistensprotein (BCRP), multidrug-resistensprotein (MRP)-transporter MRP1, MRP2 eller MRP3, organisk aniontransporter (OAT) OAT1 og OAT3, organisk aniontransporterende polypeptid 1B1 (OATP1B1), organisk kationtransporter (OCT) OCT1 og OCT2, multidrug and toxin extrusion transport protein (MATE) MATE1 eller organisk kationtransporter novel (OCTN) OCTN1 og OCTN2.
In vitro studies indicate that lenalidomide is not a substrate of human breast cancer resistance protein (BCRP), multidrug resistance protein (MRP) transporters MRP1, MRP2, or MRP3, organic anion transporters (OAT) OAT1 and OAT3, organic anion transporting polypeptide 1B1 (OATP1B1), organic cation transporters (OCT) OCT1 and OCT2, multidrug and toxin extrusion protein (MATE) MATE1, and organic cation transporters novel (OCTN) OCTN1 and OCTN2.
In vitro-studier indikerer, at lenalidomid ikke har en hæmmende virkning på human galdesalt- eksportpumpen (BSEP), BCRP, MRP2, OAT1, OAT3, OATP1B1, OATP1B3 og OCT2.
In vitro studies indicate that lenalidomide has no inhibitory effect on human bile salt export pump (BSEP), BCRP, MRP2, OAT1, OAT3, OATP1B1, OATP1B3, and OCT2.
In vitro-studier indikerer, at osimertinib hovedsageligt metaboliseres af CYP3A4 og CYP3A5.
In vitro studies indicate that osimertinib is metabolized predominantly by CYP3A4, and CYP3A5.
In vitro-studier indikerer, at pemetrexed udskilles ved aktivt sekretion via OAT3 (organisk aniontransporter).
In Vitro studies indicate that pemetrexed is actively secreted by OAT3 (organic anion transporter.
In vitro-studier indikerer, at raltegravir ikke er et substrat for CYP-enzymer, ikke hæmmer CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 eller CYP3A, ikke inducerer CYP3A4 og ikke hæmmer P-glykoproteinmedieret transport.
In vitro studies indicate that raltegravir is not a substrate of cytochrome P450 (CYP) enzymes, does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A, does not induce CYP3A4 and does not inhibit P-glycoprotein-mediated transport.
In vitro-studier indikerer, at tolvaptan er et substrat og en kompetitiv hæmmer af P-glykoprotein (P-gp).
In vitro studies indicate that tolvaptan is a substrate and competitive inhibitor of P-glycoprotein (P-gp)
In vitro-studier indikerer, at tolvaptan og dets oxobutylsyremetabolit kan have potentialet for at hæmme OATP1B1-, OATP1B3-, OAT3-, BCRP- og OCT1-transportører.
In vitro studies indicate that tolvaptan or its oxobutyric metabolite may have the potential to inhibit OATP1B1, OATP1B3, OAT3, BCRP and OCT1 transporters.
In vitro-studier med anvendelse af humane levermikrosomer viser ingen eller lille (<25 %) hæmning af CYP isozymerne 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 eller 3A4 ved koncentrationer af zonisamid, der er omkring 2 gange eller større end klinisk relevante ubundne serumkoncentrationer.
In vitro studies using human liver microsomes show no or little (< 25%) inhibition of cytochrome P450 isozymes 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 or 3A4 at zonisamide levels approximately two-fold or greater than clinically relevant unbound serum concentrations.
In vitro-studier med anvendelse af humane levermikrosomer viser ingen eller lille (<25 %) hæmning af CYP-isozymerne 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 eller 3A4 ved koncentrationer af zonisamid, der er omkring 2 gange eller større end klinisk relevante ubundne serumkoncentrationer.
In vitro studies using human liver microsomes show no or little (<25%) inhibition of cytochrome P450 isozymes 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 or 3A4 at zonisamide levels approximately two- fold or greater than clinically relevant unbound serum concentrations.
In vitro-studier med dyrkede humane hepatocytter har vist, at IL-6 forårsager et fald i CYP1A2, CYP2C9, CYP2C19 og CYP3A4 enzym-ekspression.
In vitro studies with cultured human hepatocytes demonstrated that IL-6 caused a reduction in CYP1A2, CYP2C9, CYP2C19, and CYP3A4 enzyme expression.
In vitro-studier med dyrkede, humane hepatocytter har vist, at IL-6 medførte en reduktion i ekspressionen af enzymerne CYP1A2, CYP2C9, CYP2C19 og CYP3A4.
In vitro studies with cultured human hepatocytes demonstrated that IL-6 caused a reduction in CYP1A2, CYP2C9, CYP2C19 and CYP3A4 enzyme expression.
In vitro-studier med humane levermikrosomer (HLM’er) tyder på, at darunavir primært gennemgår oxidativ metabolisme.
In vitro experiments with human liver microsomes (HLMs) indicate that darunavir primarily undergoes oxidative metabolism.
In vitro-studier med humane levermikrosomer indikerer, at CYP1A1 er det primære enzym, der er ansvarlig for 7-hydroxylationen af granisetron, hvorimod CYP3A4 bidrager til 9’desmethylation.
In vitro studies using human liver microsomes indicate that CYP1A1 is the major enzyme responsible for the 7-hydroxylation of granisetron, whereas CYP3A4 contributes to 9’desmethylation.
In vitro-studier og kliniske farmakokinetiske interaktionsstudier har vist et lavt potentiale for CYP- medierede interaktioner, hvor emtricitabin og tenofovirdisoproxilfumarat er involveret sammen med andre lægemidler.
In vitro and clinical pharmacokinetic interaction studies have shown the potential for CYP-mediated interactions involving emtricitabine and tenofovir disoproxil fumarate with other medicinal products is low.
In vitro-studier pegede på, at ibrutinib ikke er substrat for P-gp eller for andre væsentlige transportører med undtagelse af OCT2.
In vitro studies indicated that ibrutinib is not a substrate of P-gp, nor other major transporters, except OCT2.
In vitro-studier påviste, at alogliptin hverken er et substrat eller en hæmmer af involverede transportere af betydning for tilstedeværelse af lægemidler i nyrerne: organisk aniontransporter-1, organisk aniontransporter-3 og organisk kationtransporter-2 (OCT2).
In studies in vitro, alogliptin was found to be neither a substrate nor an inhibitor of key transporters associated with drug disposition in the kidney: organic anion transporter-1, organic anion transporter-3 or organic cationic transporter-2 (OCT2).
In vitro-studier påviste, at alogliptin hverken er et substrat eller en hæmmer af nøgle transportører af betydning for tilstedeværelse af lægemidler i nyrerne: organisk aniontransporter-1, organisk aniontransporter-3 og organisk kationtransporter-2 (OCT2).
In studies in vitro, alogliptin was found to be neither a substrate nor an inhibitor of key transporters associated with drug disposition in the kidney: organic anion transporter-1, organic anion transporter-3 or organic cationic transporter-2 (OCT2).
In vitro-studier viser, at bortezomib er en svag hæmmer af CYP-isozymer 1A2, 2C9, 2C19, 2D6 og 3A4.
In vitro studies indicate that bortezomib is a weak inhibitor of the cytochrome P450 (CYP) isozymes 1A2, 2C9, 2C19, 2D6 and 3A4.
In vitro-studier viser, at duloxetin ikke inducerer CYP3A's nedbrydende aktivitet.
Results of in vitro studies demonstrate that duloxetine does not induce the catalytic activity of CYP3A.
In vitro-studier viser, at eltrombopag er en hæmmer af OATP1B1- og BCRP-transporteren, og i et klinisk lægemiddelinteraktionsstudie sås, at eltrombopag øger eksponeringen af OATP1B1- og BCRP- substratet rosuvastatin (se pkt 4.5).
In vitro studies demonstrate that eltrombopag is an inhibitor of the OATP1B1 transporter and an inhibitor of the BCRP transporter and eltrombopag increased exposure of the OATP1B1 and BCRP substrate rosuvastatin in a clinical drug interaction study (see section 4.5).
In vitro-studier viser, at eltrombopag er en hæmmer af OATP1B1- og BCRP-transporteren, og i et klinisk lægemiddelinteraktionsstudie sås, at eltrombopag øger eksponeringen af OATP1B1- og BCRP- substratet rosuvastatin (se pkt.
In vitro studies demonstrate that eltrombopag is an inhibitor of the OATP1B1 transporter and an inhibitor of the BCRP transporter and eltrombopag increased exposure of the OATP1B1 and BCRP substrate rosuvastatin in a clinical drug interaction study (see section 4.5).
In vitro-studier viser, at enzymerne CYP1A2, 2B6 og 2C9 ikke induceres, og at CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2D6 og 2E1 ikke hæmmes af lacosamid ved plasmakoncentrationer observeret i kliniske forsøg.
In vitro studies indicate that the enzymes CYP1A2, 2B6, and 2C9 are not induced and that CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2D6, and 2E1 are not inhibited by lacosamide at plasma concentrations observed in clinical trials.
In vitro-studier viser, at levetiracetam påvirker de intraneuronale Ca2+ -niveauer ved delvis hæmning af N-type Ca2+ -strømme og ved reduktion af frigivelsen af Ca2+ fra intraneuronale lagre.
In vitro studies show that levetiracetam affects intraneuronal Ca2+ levels by partial inhibition of N- type Ca2+ currents and by reducing the release of Ca2+ from intraneuronal stores.
In vitro-studier viser, at levetiracetam påvirker de intraneuronale Ca2+ niveauer ved delvis hæmning af N-type Ca2+ strømme og ved reduktion af frigivelsen af Ca2+ fra intraneuronale lagre.
In vitro studies show that levetiracetam affects intraneuronal Ca2+ levels by partial inhibition of N-type Ca2+ currents and by reducing the release of Ca2+ from intraneuronal stores.
In vitro-studier viste, at trametinib primært metaboliseres via deacetylering alene eller med monooxygenering eller i kombination med biotransformationsveje med glucuronidering.
In vitro studies demonstrated that trametinib is metabolised predominantly via deacetylation alone or with mono-oxygenation or in combination with glucuronidation biotransformation pathways.
In vitro-test har vist, at 1 g kan dække 100 cm2 med RaplixaSpray-enheden.
It is known from in vitro testing that 1 g can cover 100 cm2 using the RaplixaSpray device.
In vitro-tests viste, at brivaracetam eksponering ikke burde blive signifikant påvirket af CYP (f.eks.
In vitro assays showed that brivaracetam disposition should not be significantly affected by CYP (eg.
In vitro-transportundersøgelser har vist, at sitagliptin er et substrat for p-glykoprotein og organisk aniontransporter (OAT3).
In vitro transport studies showed that sitagliptin is a substrate for p-glycoprotein and organic anion transporter-3 (OAT3).
In vitro-undersøgelse af lægemiddelinteraktioner
In vitro assessment of drug interactions
In vitro-undersøgelser har ikke vist hæmning af nogle undertyper af cytokrom P450.
In vitro studies have shown no inhibition of any subtype of cytochrome P450.
In vitro-undersøgelser har vist, at rivaroxaban er et substrat af transportproteinerne P-gp (P- glycoprotein) og Bcrp (brystcancer-resistensprotein).
Based on in vitro investigations rivaroxaban is a substrate of the transporter proteins P-gp (P-glycoprotein) and Bcrp (breast cancer resistance protein).
In vitro-undersøgelser har vist, at rosiglitazon primært metaboliseres af CYP2C8 og i mindre omfang af CYP2C9.
In vitro studies demonstrate that rosiglitazone is predominantly metabolised by CYP2C8, with a minor contribution by CYP2C9.
In vitro-undersøgelser indikerede, at det enzym, der primært er ansvarlig for sitagliptins begrænsede metabolisering, er CYP3A4, med medvirken fra CYP2C8.
In vitro studies indicated that the primary enzyme responsible for the limited metabolism of sitagliptin was CYP3A4, with contribution from CYP2C8.
In vitro-undersøgelser indikerede, at det enzym, der primært er ansvarligt for sitagliptins begrænsede metabolisering, er CYP3A4, med medvirken fra CYP2C8.
In vitro studies indicated that the primary enzyme responsible for the limited metabolism of sitagliptin was CYP3A4, with contribution from CYP2C8.
In vitro-undersøgelser med brug af menneskelige levermikrosomer og cDNA-udtrykte P450 enzymer har vist begrænset CYP 3A4-medieret metabolisme.
In vitro studies using human liver microsomes and cDNA-expressed P450 enzymes have shown limited CYP 3A4-mediated metabolism.
In vitro-undersøgelser tyder på, at CYP3A4 primært er ansvarlig for sitagliptins begrænsede metabolisme, og at CYP2C8 medvirker hertil.
In vitro studies indicated that the primary enzyme responsible for the limited metabolism of sitagliptin is CYP3A4, with contribution from CYP2C8.
In vitro-undersøgelser tyder på, at zidovudin-resistente virusisolater kan blive zidovudin- følsomme, hvis de samtidig udvikler resistens over for lamivudin.
In vitro studies indicate that zidovudine-resistant virus isolates can become zidovudine sensitive when they simultaneously acquire resistance to lamivudine.
In vitro-undersøgelser ved anvendelse af Zirela-nebulisatorsystemet med Quinsair har vist følgende lægemiddelfremføringsegenskaber: median aerodynamisk massediameter (dråbestørrelsesfordeling): 3,56 mikrometer (1,51 geometrisk standardafvigelse), lægemiddelfremføringshastighed:
In vitro studies using the Zirela Nebuliser System with Quinsair have demonstrated the following drug delivery characteristics: mass median aerodynamic diameter (droplet size distribution):
In vitro-undersøgelser viser, at nateglinid er kraftigt bundet (97–99%) til serumproteiner, overvejende serumalbumin og i mindre grad glykoprotein α1-syre.
In vitro studies show that nateglinide is extensively bound (97–99%) to serum proteins, mainly serum albumin and to a lesser extent alpha1-acid glycoprotein.
In vitro-undersøgelser viser, at nateglinid er kraftigt bundet (97–99%) til serumproteiner, overvejende serumalbumin og i mindre grad surt α1-glykoprotein.
In vitro studies show that nateglinide is extensively bound (97–99%) to serum proteins, mainly serum albumin and to a lesser extent alpha1-acid glycoprotein.
In vitro-undersøgelser viste, at vinflunin er et P-glykoprotein (Pgp)-substrat ligesom andre vinca- alkaloider, men med en lavere affinitet.
In vitro studies showed that vinflunine is a Pgp-substrate like other vinca alkaloids, but with a lower affinity.
In vitro-undersøgelser:
In vitro studies
In vitro: Der er observeret resistens in vitro og hos nogle hiv 1-inficerede patienter på grund af udvikling af M184V/I-mutationen med emtricitabin eller K65R-mutationen med tenofovir.
In vitro: Resistance has been seen in vitro and in some HIV-1 infected patients due to the development of the M184V/I mutation with emtricitabine or the K65R mutation with tenofovir.
In vitro: Hæmning af osteoblastdannelse, direkte cytostatisk og pro-apoptotisk aktivitet på tumorceller, synergistisk cytostatisk effekt med andre anti-cancermidler, anti-adhæsion-
In vitro: Inhibition of osteoblast proliferation, direct cytostatic and pro-apoptotic activity on tumour cells, synergistic cytostatic effect with other anti-cancer drugs, anti-adhesion/invasion activity.
In vivo blev kvantitativ korrelation ikke vurderet hos døende patienter mellem florbetaben (18F) - optagelse i den kortikale grå substans og aflejring af beta-amyloidplak i obduktionsprøver.
In vivo, quantitative correlation was not assessed in end-of-life patients between florbetaben (18F) uptake in cortical grey matter and the beta-amyloid deposition in autopsied samples.
In vivo eksponering for glycerolphenylbutyrat har resulteret i reduceret systemisk eksponering for midazolam på cirka 32 % og øget eksponering for 1-hydroxy-metabolitten af midazolam, hvilket indikerer, at steady state dosering af glycerolphenylbutyrat resulterer i CYP3A4- induktion.
In vivo exposure to glycerol phenylbutyrate has resulted in decreased systemic exposure to midazolam of approximately 32% and increased exposure to the 1-hydroxy metabolite of midazolam, suggesting that steady-state dosing of glycerol phenylbutyrate results in CYP3A4 induction.
In vivo falder produktionen af hydroxymetabolitten tifoldigt hos mennesker, der har ineffektive mutationer af CYP2C19, mens brivaracetam selv stiger med 22 % eller 42 % hos personer, hvor et eller begge alleler er muteret.
In vivo, in human subjects possessing ineffective mutations of CYP2C19, production of the hydroxy metabolite is decreased 10- fold while brivaracetam itself is increased by 22 % or 42 % in individuals with one or both mutated alleles.
In vivo førte samtidig administration af Numient med op til 40 % volumen-til-volumen (v/v) alkohol ikke til dosis-dumping af levodopa eller carbidopa.
In vivo, co-administration of Numient with up to 40% volume-to-volume (v/v) alcohol did not result in dose- dumping of levodopa or carbidopa.
In vivo gav robenacoxib-injektionsopløsning en markant hæmning af COX-2- aktiviteten og havde ingen virkning på COX-1-aktiviteten.
In vivo, robenacoxib solution for injection produced marked inhibition of COX-2 activity and had no effect on COX-1 activity.